Seeking Alpha
Long/short equity, long only, short only, growth
Profile| Send Message|
( followers)  

Some may call earnings season the most wonderful time of the year, and others may just plain hate it. But whatever your preference may be, it's always a very busy time of the year for all. Some industries shut down after certain hours, but healthcare is not one of them. As we get ready for a big week of earnings, here are six healthcare names reporting this week. I'll focus on the one big name and discuss five others afterwards.

Johnson & Johnson (NYSE:JNJ) - Tuesday, before the bell: The healthcare giant, that some call a consumer name, will report earnings Tuesday morning for the fourth quarter and full year. For the quarter, revenues are projected to rise by 4.1% to nearly $16.3 billion. Earnings per share are expected to rise by seven cents to $1.10. It's not unexpected to see earnings per share rise greater than revenues for a name like this, as huge stock buybacks will eliminate some of the outstanding shares. The company has beaten earnings expectations in the past three quarters, and matched earnings expectations in last year's 4th quarter results that projected the same $1.03.

For the full year, revenues at the company are expected to rise by 5.7% to just over $65 billion. However, shrinking margins will cause earnings per share to increase at a slightly slower rate, increasing 20 cents a share to $4.96 for the full year. Even the buybacks cannot help when margins are contracting this much.

2012 numbers are projected to show growth as well, although not as much on the revenue side. Current expectations call for revenues to increase by 4.5% to $68 billion, while earnings per share are estimated to increase to $5.22. We'll know how much that is in percentage terms after they report the 2011 number.

Johnson and Johnson is a very stabile stock, and many investors buy it for its excellent 3.5% dividend, a dividend that grows every year. The stock is just $3 off its 52-week high, although for a low-beta name, that can be a few days of trading. Obviously, this is not a name to trade for earnings, because we shouldn't get a huge move in either direction. I like the name, but you probably can get it cheaper, in the low $60s, over the next couple of months. Enter wisely at those levels.

Abbott Labs (NYSE:ABT) - Wednesday, before the bell: The major drug manufacturer will post its fiscal fourth quarter and full year results in the middle of the week. Fourth quarter revenues are projected to rise by 6.4% to $10.61 billion. Earnings per share are estimated to increase at almost twice that rate, from $1.30 to $1.44. For the full year, revenues are projected to rise by 11% to just over $39 billion. Earnings per share are expected to rise from $4.17 to $4.65, a little more growth than revenues. Looking forward to 2012, revenues are currently projected to rise by 4.3%, with earnings growth expected to be double that amount.

Baxter International (NYSE:BAX) - Thursday, before the bell: The large cap healthcare name will report its fourth quarter and full year results later in the week. For the quarter, revenues are estimated to rise by 2.3% to $3.58 billion, with earnings per share increasing 6 cents to $1.17. For the full year, revenues are expected to climb 6.1% to $13.86 billion, and earnings per share to increase from $3.98 to $4.31. For 2012, revenues are projected to climb by slightly more than three percent. Earnings per share are expected to grow at a rate twice that of the year's revenue growth.

Amgen (NASDAQ:AMGN) - Thursday, after the bell: The biotech giant will report fourth quarter and full year results later in the week. For the quarter, revenues are projected to rise by 2% to $3.92 billion. Earnings per share are expected to increase by six cents to $1.23. For the full year in 2011, revenues are estimated to increase by slightly more than three percent to $15.5 billion. Earnings per share are expected to rise by a smaller rate, increasing twelve cents to $5.33. Revenue growth is expected to increase slightly more in 2012 than 2011 numbers, with earnings growth expected in the low teens, percentage wise.

St. Jude Medical (NYSE:STJ) - Wednesday, prior to opening bell: The medical device and equipment firm will report in the middle of the week. For the fourth quarter, revenues are projected to increase by nearly four percent to $1.9 billion. Earnings per share are expected to rise by nine cents to 84 cents a share. For the full year, revenues are projected to rise by 8.6% to over $5.6 billion, with earnings growth at a similar rate. Earnings per share are forecast to rise from $3.01 to $3.27. Revenue growth in 2012 is currently forecast to be less than half of what it was in 2011, but earnings per share are expected to rise at a similar rate to the growth seen in 2011.

Stryker (NYSE:SYK) - Tuesday, after the bell: The medical technology firm will announce its fourth quarter and full year results this week. For the quarter, revenues are projected to rise by 11% to $2.22 billion. Earnings per share are expected to increase from $0.93 to $1.02. For the full year, revenues are forecast to climb 13.5% to $8.3 billion. Earnings per share numbers are forecast for similar growth, rising 40 cents a share to $3.73. Revenue growth is only projected to be 5% in 2012, but earnings per share numbers are forecast to rise by twice that amount.

Source: JNJ Leads Field Of Healthcare Names Reporting Earnings This Week